Clinical Features of Endocrine Disorders with Immune Checkpoint Inhibitor in Patients with Non-Small Cell Lung Cancer

• Published in: Gan to kagaku ryoho Vol. 50; no. 2; p. 177
• Main Authors: Takagi, Hironori, Muto, Satoshi, Fukuhara, Mitsuro, Inomata, Sho, Watanabe, Masayuki, Ozaki, Yuki, Okabe, Naoyuki, Matsumura, Yuki, Shio, Yutaka, Saito, Haruka, Ohe, Keitaro, Iyoda, Tomokazu, Shimabukuro, Michio, Kuroda, Junko, Suzuki, Hiroyuki
• Format: Journal Article
• Language: Japanese
• Published: Japan 01-02-2023
• Subjects: Carcinoma, Non-Small-Cell Lung - drug therapy; Endocrine System Diseases; Female; Humans; Immune Checkpoint Inhibitors - therapeutic use; Lung Neoplasms - drug therapy; Male; Neoplasm Recurrence, Local - drug therapy; Retrospective Studies
• ISSN: 0385-0684

Immune checkpoint inhibitors(ICIs)could cause immune-related adverse events(irAEs), of which endocrine disorders are relatively common. Symptoms include fatigue, anorexia, and shock, making diagnosis and treatment difficult. This study aimed to analyze the characteristics of patients with non-small cell lung cancer concomitant with endocrine disorders as irAEs. In total, 83 patients who were administered ICIs for advanced or postoperative recurrent non-small cell lung cancer between February 2016 and February 2021 were identified. We retrospectively studied the clinical course and findings of 7 patients who developed endocrine disorders after treatment. Four patients had hypopituitarism, and 3 patients had thyroid dysfunctions. There were 6 male patients and 1 female patient. Regarding anticancer agents, 5 patients received ICI alone, and 2 patients received ICI plus cytotoxic chemotherapies. The patients received treatment from the irAE treatment team in our hospital, and 5 of 7 patients could were able to be readministered ICIs. Endocrine disorders as irAEs require collaboration with specialized departments for early diagnosis and treatment.